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Purpose: To assess baseline predictors and consequences of medication non-adherence in 
the treatment of pediatric patients with attention-deficit/hyperactivity disorder (ADHD) from 
Central Europe and East Asia.
Patients and methods: Data for this post-hoc analysis were taken from a 1-year prospec-
tive, observational study that included a total of 1,068 newly-diagnosed pediatric patients 
with ADHD symptoms from Central Europe and East Asia. Medication adherence during the 
week prior to each visit was assessed by treating physicians using a 5-point Likert scale, and 
then dichotomized into either adherent or non-adherent. Clinical severity was measured by 
the Clinical Global Impressions-ADHD-Severity (CGI-ADHD) scale and the Child Symptom 
Inventory-4 (CSI-4) Checklist. Health-Related Quality of Life (HRQoL) was measured using 
the Child Health and Illness Profile-Child Edition (CHIP-CE). Regression analyses were used 
to assess baseline predictors of overall adherence during follow-up, and the impact of time-
varying adherence on subsequent outcomes: response (defined as a decrease of at least 1 point 
in CGI), changes in CGI-ADHD, CSI-4, and the five dimensions of CHIP-CE.
Results: Of the 860 patients analyzed, 64.5% (71.6% in Central Europe and 55.5% in East 
Asia) were rated as adherent and 35.5% as non-adherent during follow-up. Being from East Asia 
was found to be a strong predictor of non-adherence. In East Asia, a family history of ADHD 
and parental emotional distress were associated with non-adherence, while having no other 
children living at home was associated with non-adherence in Central Europe as well as in the 
overall sample. Non-adherence was associated with poorer response and less improvement on 
CGI-ADHD and CSI-4, but not on CHIP-CE.
Conclusion: Non-adherence to medication is common in the treatment of ADHD, particularly 
in East Asia. Non-adherence was associated with poorer response and less improvement in 
clinical severity. A limitation of this study is that medication adherence was assessed by the 
treating clinician using a single item question.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is among the most prevalent mental dis-
orders in childhood and adolescence, affecting 6% to 8% of this population worldwide.1,2 
It is characterized by the core symptoms of hyperactivity, impulsivity, and inattention,3 
and is now recognized as a lifelong, chronic disorder that can extend into adulthood 
either as the full condition or in partial remission.4 In the absence of early and appropri-
ate treatment, the disorder may also result in long-term negative consequences, such as 
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low educational achievement,  occupational or  interpersonal 
difficulties/failures, as well as an increased risk of substance 
abuse, crime, and accidental injury.5–10
A multi-disciplinary approach is often recommended 
for the management of ADHD, in which pharmacotherapy 
can be an integral part when remedial measures alone prove 
insufficient.11 Both stimulants and non-stimulant medications 
have been proven to be effective in the treatment of ADHD, 
providing that patients adhere to the prescribed regimen.11–14 
A recent review of adherence studies, however, showed a 
high level of medication non-adherence among children/
adolescents with ADHD.15 The prevalence of medication 
non-adherence was reported to range from 13.2% to 64%, 
depending on the clinical setting, definition and assessment 
of adherence, duration of study, and characteristics of the 
study population. Although the consequences of medication 
non-adherence have been poorly documented in ADHD, 
limited evidence from the US shows the negative impact of 
non-adherence on clinical and functional outcomes.  Charach 
et al assessed the impact of adherence on outcomes in 
79 patients with ADHD, who were followed up for 5 years 
after completing a 12-month randomized controlled trial 
(RCT) of methylphenidate in the US.16 The study showed 
greater improvement in teacher-reported symptoms among 
adherent patients, compared to non-adherent patients or 
those off medication. Similarly, Marcus and Durkin also 
found an association between adherence to stimulants and 
higher academic grades, using Medicaid claims data and aca-
demic administrative records in Philadelphia (US).17 Further 
research is warranted to examine whether these findings are 
replicated in other clinical and cultural settings, and if so, 
to what extent. Furthermore, a greater understanding of the 
factors associated with non-adherence to ADHD medications 
is needed so that any avoidable risk factors can be identified 
and managed using appropriate interventions.
A variety of predictors of medication non-adherence in 
ADHD have been reported previously. These include frequent 
daily dosing,18–21 male gender,21,22 older age,18,20,21,23–25 ethnic 
minorities,25,26 lower childhood IQ,26–28 lower self-control,27 
later onset of ADHD,20 poor family support,19 family history 
of ADHD,20 maternal psychological distress,18 greater20,27,28 
or lower symptom severity,24,25 concomitant medications,21 
comorbid conditions, such as oppositional or defiant 
behavior,19,24 adverse effects,20 and privacy issues.5,18,19,29 
This evidence is again mostly from the US and Canada. 
The exceptions are two Taiwanese retrospective studies 
conducted by Gau et al.18,20 The authors earlier examined the 
extent and predictors of poor adherence to immediate-release 
methylphenidate (IR-MPH) among 307 pediatric patients 
with ADHD who had been receiving IR-MPH in Taiwan.18 
Approximately, one in four patients (25.7%) was found to 
have poor adherence. Frequent daily dosing and older age 
were found to be the main predictors of poor adherence to 
IR-MPH. Poor adherence was also associated with mater-
nal psychological distress, indifferent parenting, maternal 
overprotection/control, poor family support, less interaction 
with parents, and more problems at home. Later, Gau et al 
conducted a similar study and reported a greater rate of poor 
adherence (39.5%).20 Factors associated with poor adherence 
were older age, a family history of ADHD, later onset of 
ADHD, higher parental educational level, multi-dose admin-
istration, and more severe ADHD-related symptoms. While 
the study did not examine the impact of non-adherence to 
ADHD medications, the authors suggested that poor adher-
ence may be an important reason for sub-optimal outcomes 
in the treatment of ADHD in the region.
Using data from a 1-year large, prospective, observational 
study involving 1,068 newly-diagnosed pediatric patients 
with ADHD symptoms from Central Europe and East Asia, 
this post-hoc analysis explored predictors of medication 
non-adherence in the treatment of ADHD, and examined 
the impact of non-adherence on clinical severity and health-
related quality of life (HRQoL) measures during 12 months 
of treatment and follow-up in a naturalistic outpatient setting 
in Central Europe and East Asia.
Material and methods
Study design and patient sample
This was a 12-month, international, prospective, non-
 interventional, observational study, primarily designed 
to examine treatment patterns and health outcomes in the 
treatment of newly-diagnosed pediatric patients with ADHD 
symptoms in actual clinical practice. From October 2005 
to July 2006, 58 psychiatrists and pediatricians enrolled a 
total of 1,068 pediatric patients from eight countries across 
Central Europe and East Asia (People’s Republic of China, 
the Czech Republic, Hungary, Romania, Slovakia, South 
Korea,  Taiwan, and Turkey). This study followed the ethical 
standards of responsible local committees and regulations of 
the participating countries, and was conducted in accordance 
with the ethical principles that have their origin in the Decla-
ration of Helsinki and are consistent with Good Clinical Prac-
tice (GCP) where applicable to a study of this nature. Ethical 
Review Board (ERB) approval was obtained as required for 
observational studies wherever required by local law. The 
parents/guardians of all patients provided written informed 
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consent, and patients provided assent. Further details on the 
study design have been provided elsewhere.30–33
Child and adolescent outpatients aged 6–17 years could 
participate in the study if they presented within the normal 
course of care with ADHD symptoms, and had not been 
previously diagnosed with, or treated for, ADHD. The 
diagnosis of ADHD symptoms was made by an  investigator 
using standard diagnostic criteria (Diagnostic and Statistical 
Manual of Mental Disorders, 4th ed; text revision [DSM-IV-
TR]34 or the ICD-10 Classification of Mental and Behavioural 
Disorders. Clinical descriptions and diagnostic guidelines 
[ICD-10]).35 That is, in the clinical judgment of the investiga-
tor, participating patients were required to have hyperactive/
inattentive/impulsive symptoms/ problems  associated with 
ADHD described by DSM-IV-TR, or hyperkinetic con-
duct disorder according the ICD-10 at baseline. The study 
excluded those patients who had severe mental retardation 
(unable to attend school due to mental  disability), epilepsy 
or schizophrenia, or were participating in a different study 
that included a treatment intervention and/or investigational 
drug.
Data collection for the study occurred during visits within 
the normal course of care. The routine outpatient visit at 
which patients were enrolled served as the time for baseline 
data collection. Subsequent data collection was targeted at 
1-month after the baseline visit and then every 3 months 
(3, 6, 9, and 12 months) since the baseline visit. Patient 
demographics and clinical history were recorded at the 
baseline assessment. Clinical severity of ADHD symptoms 
was assessed by treating physicians at each visit using the 
Clinical Global Impressions-ADHD-Severity (CGI-ADHD) 
scale36 and the Category A of the Child Symptom Inven-
tory-4 Parent Checklist (CSI-4).37 The CSI-4 is made up of 
18 items related to ADHD symptoms (9 each for the ADHD-
 inattentive type [ADHD-I] and the ADHD-hyper/impulsive 
type [ADHD-HI]) that are each rated on a scale from 0 
(never) to 3 (very often) in terms of symptom  frequency. In 
the present analysis, the physician-rated version, of which 
CSI-4 scores were recorded by the treating physicians in 
consultation with parents, was used after converting them to 
norm-referenced standardized CSI-4 scores using US-based 
population norms. HRQoL was assessed using the Parent 
Report Form of the Child Health and Illness Profile-Child 
Edition (CHIP-CE).38 The CHIP-CE is a validated generic 
HRQoL measure, developed in the US and Spain. The Par-
ent Report Form assesses the health of the child from the 
perspective of their parents on five domains (Satisfaction, 
Comfort, Resilience, Risk Avoidance, and Achievement), 
which themselves are made up of 12 different subdomains. 
Similarly, norm-referenced standardized CHIP-CE T-scores 
were derived for each of the five domains using US-based 
population norms. Higher scores indicate better health.
Patients could be prescribed any treatment regimen 
by the treating physician for the treatment of their ADHD 
 symptoms. Treatment decisions were made solely at the dis-
cretion of the physician, patient, or parent/guardian, and were 
independent of study participation. In actual practice, patients 
could receive no treatment, psychotherapy, pharmacotherapy, 
a combination of psychotherapy and pharmacotherapy, or 
other treatments. The most commonly prescribed medication 
at baseline was methylphenidate (45.5% [n = 486/1,068] in 
the total sample; 69.0% [n = 486/704] in patients who were 
prescribed at least one medication). Psychotherapy included 
formal sessions of psychoeducation and counseling, cogni-
tive behavioral therapy, family therapy or psychodynamic 
therapy, which were conducted by a certified healthcare 
provider at a regular frequency for an acceptable length of 
time. Other treatments included educational interventions, 
speech therapy, occupational therapy, herbal therapy/home-
opathy, informal hypnosis, psychomotor/physiotherapy, 
electroencephalogram (EEG) biofeedback, diet exclusion, 
diet supplementation, and relaxation techniques.
Adherence
Adherence to ADHD medications during the week prior to 
each follow-up evaluation was assessed by the treating phy-
sician using information obtained during the interview, and 
categorized into one of the six groups: prescribed medica-
tion was taken (1) never, (2) occasionally, (3) some of the 
time, (4) most of the time, (5) always, and (6) not  applicable 
(ie, no medication). Patients were then re-categorized into 
two groups at each post-baseline visit: non-adherent (groups 
1, 2 and 3), and adherent (groups 4 and 5). Overall adher-
ence/non-adherence was further defined to examine baseline 
predictors of adherence during follow-up: patients, who were 
categorized as non-adherent on one or more post-baseline 
evaluations, were subsequently considered to be non-adherent 
during the follow-up period; otherwise, patients were con-
sidered to be adherent during follow-up.
Measures of the consequences  
of non-adherence
The consequences of medication non-adherence were exam-
ined by assessing the association between non-adherence/
adherence status (as a time-varying variable) and the 
following outcomes measured at a next visit: response, 
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change in symptom severity, and change in HRQoL. 
Response was defined as a decrease of at least one point 
in the CGI-ADHD. Change in clinical severity was mea-
sured using the CGI-ADHD and the CSI-4, while change 
in HRQoL was measured using each of the five domains 
of the CHIP-CE. Changes in clinical severity or HRQoL 
were measured since baseline, except for those visits where 
patients experienced worsening symptoms compared with a 
previous visit. For these visits, changes in clinical severity 
or HRQoL were measured since the previous visit in order 
to better capture the detrimental impact of non-adherence 
on the subsequent outcomes. A similar logic was also 
applied to response. If a patient achieved at least one score 
reduction in the CGI-ADHD since baseline and did not 
experience worsening symptoms compared to a previous 
visit, the patient was considered to have achieved response 
at the visit. Otherwise, the patient was considered not to 
have achieved response.
Statistical analysis
The present analysis included those patients who were 
prescribed a medication either at baseline and/or during 
follow-up (n = 860). Baseline characteristics of the two 
groups of patients by adherence status during follow-up 
were summarized using descriptive statistics (mean, standard 
deviation, percentage).
Logistic regression analysis was performed to identify 
baseline predictors of overall adherence during follow-up. 
The model included age, gender, age at first symptoms, region 
(Central Europe; East Asia), birth problems, a family history 
of ADHD, and a CGI-ADHD score. The model also included 
the following variables but only if they appeared to be sig-
nificant at P , 0.1 in univariate analyses: body mass index 
(BMI) (kg/m2), having other children living at home, mother 
having paid employment, father having paid employment, 
emotional health problems of parents/guardians due to their 
children’s behavioral problems, having been truant in the 
past 4 weeks, having been involved in bullying (as a bully) 
in the past 4 weeks, having primary care visits for behavioral 
problems in the past 4 weeks, having been invited to social 
activities in the past 4 weeks, and a CSI-4 score.
Generalized estimating equation (GEE) regression mod-
els with exchangeable correlation structure were employed 
to analyze the consequences of non-adherence on response, 
and changes in clinical severity and HRQoL, controlling for 
patient demographics and visits. The models included the 
same covariates as listed above, plus visits and adherence 
as a time-varying covariate. The variable included here was 
not overall adherence during follow-up but adherence at the 
visit before the outcome was assessed.
All analyses were repeated for each region (ie, Central 
Europe and East Asia, respectively). In addition, sensitivity 
analyses were carried out by including a subset of patients, 
(1) who initiated pharmacotherapy at baseline (75.1%, 
n = 646); and (2) who were considered to be ADHD cases 
at baseline (85.1%, n = 732). An ADHD case was defined 
as the number of counts for “often” and “very often” in the 
nine questions for ADHD-I greater than or equal to six and/or 
that in the nine questions for ADHD-HI $6.
All statistical analyses were conducted using SAS 
version 9.1 (SAS Institute, Cary, NC, USA).
Results
Patient characteristics
A total of 860 patients, who initiated pharmacotherapy 
either at baseline and/or during follow-up, were included in 
this analysis (n = 485 for Central Europe, and n = 375 for 
East Asia). Approximately three-quarters of these patients 
(75.1%, n = 646) initiated pharmacotherapy with/without 
psychotherapy at baseline. Of the remaining 214 patients, 
86 patients initiated either psychotherapy (n = 45) or other 
treatment (n = 41), and 128 patients had no treatment docu-
mented at baseline.
More than one in three patients (35.5%, n = 305) were 
considered to be non-adherent during follow-up. In East 
Asia, almost half of the patients (44.5%, n = 167) were 
considered to be non-adherent during follow-up, which was 
much higher than the rate of overall non-adherence in Central 
Europe (28.5%, n = 138, P , 0.001). Table 1 summarizes 
the baseline patient characteristics by adherence status during 
follow-up. A higher percentage of patients who were non-
adherent during follow-up were living in East Asia, had a 
higher BMI, had no other children living at home, and had 
parents/guardians experiencing emotional difficulties due to 
their child’s behavioral problems.
Predictors of non-adherence/adherence 
during follow-up
Table 2 shows the results of logistic regression, which exam-
ined the predictors of non-adherence to ADHD medication 
during follow-up. Patients living in East Asia were more 
likely to be non-adherent during follow-up, compared with 
those in Central Europe (odds ratio [OR] = 0.55; 95% confi-
dence interval [CI] = 0.36, 0.84; P = 0.005). Among patients 
living in East Asia, a family history of ADHD (OR = 0.57, 
95% CI = 0.33, 0.96; P = 0.036), and parental emotional 
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problems (OR = 0.50; 95% CI = 0.29, 0.87; P = 0.014) were 
associated with non-adherence, while having no other chil-
dren living at home was associated with non-adherence in 
Central Europe (OR = 1.93; 95% CI = 1.06, 3.50; P = 0.030) 
as well as in the overall sample (OR = 1.66; 95% CI = 1.12, 
2.45; P = 0.011).
Consequences of non-adherence/
adherence
Table 3 summarizes the associations between adherence 
to ADHD medications and subsequent outcomes during 
follow-up, adjusted for baseline patient characteristics. 
The models included adherence as a time-varying covari-
ate: each outcome was related to the adherence rating of 
the previous assessment visit. Compared to non-adherent 
patients, adherent patients were more likely to achieve 
response during follow-up (OR = 1.52; 95% CI = 1.14, 
2.02; P = 0.004). In addition, they had greater improve-
ment in symptom severity, measured using the CGI-ADHD 
(estimate = −0.35; 95% CI = −0.51, −0.20; P , 0.001) 
and the CSI-4 (−2.98; 95% CI = −4.79, −1.17; P = 0.001). 
However, there were no significant differences in any of 
the domains of the CHIP-CE between adherent and non-
adherent patients, although the directions of the estimates 
indicated greater improvement in all dimensions of the 
CHIP-CE in adherent patients. The results remained 
largely consistent when the analyses were conducted 
on (1) patients living in East Asia and Central Europe, 
respectively, (2) patients defined as ADHD cases, and 
Table 1 Baseline patient characteristics by adherence status 
during follow-up
Baseline characteristic Non-adherent  
during follow- 
up (n = 305)
Adherent  
during follow- 
up (n = 555)
Age, mean (SD) 9.29 (2.67) 8.98 (2.48)
Male 83.83% 80.37%
Age at first symptoms,  
mean (SD)
5.51 (2.32) 5.45 (2.41)
Being from East Asia  
(versus Central Europe)*
54.75% 37.48%
BMI (kg/m2), mean (SD)* 18.71 (3.79) 18.13 (3.62)
Birth problems 28.81% 28.22%
Family history of ADHD 48.79% 48.36%
Having other children living  
at home*
48.45% 63.41%
CGI-ADHD, mean (SD) 4.58 (0.96) 4.50 (1.00)
CSI-4 category A  
(standardized), mean (SD)
76.10 (10.57) 76.50 (10.65)
Paid employment (mother) 72.91% 68.27%
Paid employment (father) 90.97% 87.27%
Parental emotional distress due  
to their children’s behavioral  
problems*
57.97% 45.16%
Being truant in the past 4 weeks 9.89% 7.63%
Being involved in bullying  
(as a bully) in the past 4 weeks
22.85% 22.98%
Primary care visit in the past  
4 weeks for behavioral problems
15.00% 12.92%
Being invited to social activity  
in the past 4 weeks
60.14% 54.98%
Notes: Data were presented as percentage or mean (standard deviation) as 
appropriate. *Significant at P , 0.05.
Abbreviations: BMI, body mass index; ADHD, attention-deficit/hyperactivity 
disorder; CGI-ADHD, Clinical Global Impressions-ADHD-Severity; CSI-4, Child 
Symptom Inventory-4 Parent Checklist; SD, standard deviation.
Table 2 Association between overall adherence during follow-up 
and baseline patient characteristics
Variables ORa OR 95% CI P-value
Age 0.993 0.918, 1.075 0.8703
Year at first symptoms 0.954 0.876, 1.040 0.2856
Male 0.709 0.438, 1.149 0.1629
Being from East Asia  
(versus Central Europe)*
0.549 0.361, 0.836 0.0051
Having birth problems 1.286 0.862, 1.919 0.2179
Family history of ADHD 0.806 0.545, 1.192 0.2802
Being involved in bullying  
(as a bully)
0.773 0.497, 1.203 0.2547
cgi-ADhD 1.057 0.876, 1.275 0.5650
BMI 0.957 0.908, 1.008 0.0972
Having other children living  
at home*
1.658 1.124, 2.446 0.0108
Parental emotional problems 0.818 0.554, 1.209 0.3139
Notes: *Significant at P , 0.05. aOr .1 indicates a positive association with overall 
adherence.
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; BMI, body mass 
index; CGI-ADHD, Clinical Global Impressions-ADHD-Severity; CI, confidence 
interval; OR, odds ratio.
Table 3 Summary of associations between adherence to ADHD 
medication and subsequent outcomes during follow-up
Outcomes OR 95% CI P-value
responsea 1.516 1.140, 2.017 0.0042
Estimates 95% CI P-value
Change in clinical severityb
cgi-ADhD −0.353 −0.506, −0.200 ,0.001
CSI-4 A category –2.980 −4.787, −1.172 0.0012
Change in CHIP-CE five domainsc
satisfaction 1.507 −0.011, 3.025 0.0517
comfort 0.988 −0.590, 2.565 0.2198
Risk avoidance 0.958 −0.592, 2.507 0.2257
resilience 1.213 −0.223, 2.649 0.0977
Achievement 0.192 −1.096, 1.479 0.7705
Notes: aOr .1 indicates a higher odds of achieving response in adherent patients; 
bestimate ,0 indicates greater improvement in clinical severity among adherent 
patients; cestimate .0 indicates greater improvement in health-related quality of life 
(CHIP-CE) among adherent patients.
Abbreviations: ADHD, Attention-Deficit/Hyperactivity Disorder; OR, odds ratio; 
CI, confidence interval; CGI-ADHD, Clinical Global Impressions-ADHD-Severity; 
CSI-4, Child Symptom Inventory-4 Parent Checklist; CHIP-CE, Child Health and 
Illness Profile-Child Edition.
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(3) patients who initiated pharmacotherapy at baseline 
(data not shown).
Discussion
The results of this large 1-year observational study revealed 
a high prevalence of medication non-adherence (35.5%) 
during the treatment of newly-diagnosed children and 
adolescents with ADHD symptoms in Central Europe and 
East Asia. In particular, almost half of the patients from 
East Asia (44.5%) were found to be non-adherent during 
follow-up. This was significantly higher than the rate of 
overall medication non-adherence found in Central Europe 
(28.5%). More importantly, our findings confirmed the 
negative impact of non-adherence on achieving response and 
symptom improvement. A family history of ADHD, parental 
psychological distress, and having no other children living at 
home were identified as potential risk factors of medication 
non-adherence in Central Europe and/or East Asia.
Whilst the rate of medication non-adherence in our study 
(35.5%) was within the range reported in other studies, our 
rate for East Asia (44.5%) was slightly higher than those 
reported in two Taiwanese retrospective studies, which are the 
only studies that have assessed the level of non-adherence to 
ADHD medication in this region.18,20 Gau et al examined the 
extent and predictors of poor adherence to IR-MPH among 
307 pediatric patients with ADHD who had been receiv-
ing IR-MPH in Taiwan.18 Poor adherence was defined as 
maternal reports of a child missing more than 14 days of any 
dose of IR-MPH on a daily basis during the previous month. 
Approximately, one in four patients (25.7%) was found to 
have poor adherence. Later, they conducted a similar study 
that involved a total of 607 pediatric patients with ADHD 
in Taiwan.20 Poor adherence to IR-MPH was defined as 
missing one or more doses on a school day on two or more 
days per week during the previous four weeks. The rate of 
poor adherence was reported to be 39.5%. Although these 
rates are slightly lower than ours, this may not be surprising 
since our definition of overall medication non-adherence 
was based on a longer time frame (ie, up to 12 months) than 
theirs (ie, maternal reports of a child missing pills during the 
previous month). Nevertheless, these studies also confirm that 
non-adherence to medication is common in the treatment of 
school-aged children with ADHD in East Asia.
It is, however, not clear why non-adherence to ADHD 
medication is more prevalent in East Asia compared to 
Central Europe. It should be highlighted that this was not all 
explained by differences in baseline patient characteristics 
between the two regions. A recent study, based on the opinions 
and feedback of international leaders in developmental psy-
chopathology research, revealed a great deal of variation in 
ADHD diagnosis rates and treatment practices across and 
within countries.39 This study also demonstrated how social 
context including historical, cultural, and economic factors 
greatly influences perceptions, diagnosis, and treatment of 
ADHD. For example, the following are salient characteristics 
of diagnosis and treatment patterns in the  People’s Republic 
of China, which are crucial in understanding the current 
treatment practices and outcomes of ADHD in that country: 
high acceptance of herbal treatments (Traditional Chinese 
medicines), high levels of stigma attached to mental illness, 
a lack of training in the treatment of ADHD among medical 
and mental health professionals, and strong controls on poten-
tially addictive medications such as stimulants.39 Indeed, the 
Shanghai Health Bureau and relevant insurance regulations 
in the People’s Republic of China mandate that any meth-
ylphenidate prescriptions be given for a maximum of only 
2 weeks, and thus frequent follow-up is necessary for further 
prescriptions.39 Such stringent guidelines can curtail the use of 
medication for the treatment of ADHD, and also discourage a 
long-term treatment if it incurs extra out-of-pocket payments 
due to frequent office visits required.
In addition, many parents of children/adolescents with 
ADHD in East Asia tend to take personal responsibility 
for their children’s behavioral problems and have nega-
tive attitudes towards the use of medications for ADHD on 
cultural grounds, as indicated in a recent literature review, 
although the review focused mainly on parents and teachers 
of school-aged children with ADHD in South Korea and the 
US.40 The review also highlighted that South Korean parents 
tended to be more concerned about their children’s academic 
performance, rather than behavioral problems, while US 
parents tended to be more concerned about their children’s 
behavioral problems mainly due to reduced independence 
and autonomy of their children, which are important values 
in that culture. It also reported that the use of medications 
was more accepted by parents in the US because of their 
tendency to believe that the medications can improve their 
children’s behavioral problems. This observation may also 
explain the association between parental psychological 
distress and medication non-adherence found in our study 
(for East Asia) and similarly in Gau et al’s.18 Parents who 
suffer from psychological distress due to their children’s 
behavioral problems are more likely to be those who also 
take heavy responsibility for their children’s problems and 
make excessive parental involvements. It is possible that 
these types of parents are more skeptical about the benefits 
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of drug treatment for ADHD, and also more concerned about 
adverse effects, potentially leading to high levels of medica-
tion non-adherence in their affected children.
Another predictor of non-adherence identified among 
East Asian patients was a family history of ADHD, which is 
again consistent with the study by Gau et al.12 Although the 
reason for this association is still unclear, Gau et al specu-
lated that this relationship may be suggestive of decreased 
organization and monitoring of medication compliance in 
the context of familiar ADHD traits. Further research is 
clearly required to confirm this relationship and explore the 
underlying mechanism.
Parental psychological distress and a family history 
of ADHD were, however, not associated with medication 
non-adherence in Central Europe and in the overall sample. 
Instead, having no other children living at home was associ-
ated with non-adherence in both cases. This association may 
imply that parents in such family have less time to provide 
other behavioral interventions at home for their children 
with ADHD, thereby being more reliant on pharmacologic 
 treatment. Alternatively, more children could mean more con-
flicts within the family, which can increase the need to control 
behavioral problems of children with ADHD. We also cannot 
exclude the possibility that the other children living at home 
act as additional caregivers who can help remind patients 
to take their medication. Notably, this association was not 
found in a subset of East Asian patients, possibly because 
many families in East Asia have an only child, especially in 
the People’s Republic of China due to the government’s one 
child policy. In addition, it should be noted that our study did 
not show the association between medication non-adherence 
and other risk factors previously identified, such as older 
age18,20,21,23–25 and male gender,21,22 although the directions 
of the associations were consistent with previous studies. 
Moreover, important predictors of non-adherence previously 
identified, such as frequent daily dosing, were not included, as 
these parameters were not assessed. Further research, prefer-
ably culturally-sensitive, is warranted to better identify risk 
factors of medication non-adherence for optimal treatment 
outcomes in ADHD.
Our study also demonstrated the negative impact of medi-
cation non-adherence on achieving response and symptom 
improvement in the treatment of newly-diagnosed pediat-
ric patients with ADHD symptoms in Central Europe and 
East Asia. This finding was consistent with previous studies 
showing similar impacts of non-adherence in ADHD.16,24 
Charach et al assessed the impact of adherence on outcomes 
in 79 patients with ADHD, who were followed up for 5 years 
after completing a 12-month RCT of methylphenidate in 
the US.16 The study showed greater improvement in teacher-
reported symptoms among adherent patients, compared to 
non-adherent patients or those off medication. Using data 
from a 13-week RCT with methylphenidate conducted in 
Europe, Kooij et al also showed that non-adherence is a sig-
nificant predictor of reduced response to treatment, although 
the study focused on the adult ADHD population.4 Our study, 
however, did not find a significant association between adher-
ence and improvement in HRQoL, although the associations 
with all five domains of the CHIP-CE (Satisfaction, Comfort, 
Resilience, Risk Avoidance, and Achievement) were in the 
expected directions. While there is no study that specifi-
cally looked at the impact of non-adherence on HRQoL in 
ADHD, Marcus and Durkin demonstrated an association 
between adherence to stimulants and higher academic grades 
among school-aged children with ADHD in the US, using 
 Medicaid claims data and academic administrative records in 
 Philadelphia.17 Taken together, more efforts should be made 
to improve communication with patients and their parents/
caregivers about the importance of medication adherence as an 
effective strategy to achieve optimal treatment outcomes.
There are several limitations that should be taken into 
account when interpreting these results. First, this study 
was originally not designed to assess medication adherence 
in ADHD but other treatment outcomes and patterns. These 
results can, therefore, only be considered as secondary 
 analyses. Second, although this observational study included 
more than one thousand patients (n = 860 in this current 
analysis), they may not be representative of the pediatric 
patients with ADHD in Central Europe and East Asia. Third, 
the patients included in our study were those with ADHD 
symptoms, not ADHD cases. The sensitivity analyses, which 
included patients with ADHD cases using the CSI-4 cut-off 
points (85%), provided consistent results, however. Fourth, 
assessment of adherence was based on physician clinical 
judgment only, rather than with an objective measure of 
adherence, such as pill counts. Therefore, the rate of non-
adherence may have been underestimated, and thereby the 
impact of non-adherence as well (ie, the difference in clini-
cal outcomes between adherent patients and non-adherent 
patients). In addition, patients and their families had to be 
willing to participate in this relatively long-term follow-up 
study, implying that they could be more compliant to the 
treatment regimen than a representative clinical sample. 
Fifth, although our study demonstrated the negative impact 
of medication non-adherence on clinical outcomes, it has 
been suggested that physician assessment of  adherence 
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may be influenced by the clinical state of the patient; that 
is,  physicians assume that patients who are doing better 
in terms of symptoms are taking more of their medication 
than patients who are not doing so well.41 Finally, given the 
observational design, the associations found in our study do 
not imply causal relationships.
Conclusion
Despite these limitations, the present study highlights a high 
level of medication non-adherence in the treatment of ADHD, 
particularly in East Asia. Being from East Asia, amongst other 
clinical and demographic factors, was found to be the stron-
gest predictor of medication non-adherence. A family history 
of ADHD and parental psychological distress were found to 
contribute to the high level of medication non-adherence in 
this region, whereas having no other children living at home 
was identified as a risk factor of medication non-adherence in 
Central Europe. Our findings also emphasize the importance 
of adherence to ADHD medication in achieving response and 
symptom improvement. If treatment outcomes are considered 
to be suboptimal, clinicians should consider not only inad-
equate effectiveness or adverse effects but also poor adher-
ence to medication. They should also pay particular attention 
to those patients who have a higher chance of non-adherence, 
and if possible, implement strategies, preferably culturally 
sensitive ones, to address modifiable risk factors associated 
with medication non-adherence. Furthermore, more efforts 
should be made for more effective communication with 
patients and their parents/caregivers to discuss the benefits 
and risks of drug treatment and the importance of medica-
tion adherence.
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